F-star asset-centric spin-out to target HER2
This article was originally published in Scrip
Executive Summary
Making the transition from platform- to product-based operation is a quantum operation, at least for Cambridge antibody company, F-star. The company has won €9.4m from its existing investor pool but the money will go into a separate and unencumbered asset-development vehicle, F-star Alpha which will operate virtually in developing a few of the company's bi-specific antibody candidates. And the lead program will take F-star Alpha into the increasing crowded area of Her2-targeted cancer therapies.